BIOKINE THERAPEUTICS

Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. Biokine’s lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in Phase IIa clinical trial for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML),... as well as a Phase I clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. Biokine has a knowhow technologies, and a pipeline for the development of therapeutics targeting cancer. Biokine intends to advance the development of its pipeline into the clinic by establishing collaborations with other companies and conducting fundraising activities from private and public agencies.

#People #Website #More